In a research report published today, analyst Jonathan Aschoff of Brean Capital maintained a Buy rating on Pacira (NASDAQ:PCRX) with a $111 price target, which represents a …
In a research report published today, Brean Capital analyst Jonathan Aschoff reaffirmed a Sell rating on Rockwell Medical (NASDAQ:RMTI) with a $4.00 price target, which represents …
In a research report published today to investors, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 …
In a research note published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, as the …
In a research published today, Brean Capital analyst Jonathan Aschoff downgraded shares of Endocyte (NASDAQ:ECYT) from a Buy to a Hold rating, on …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 price …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Repros Therapeutics (NASDAQ:RPRX) with a price target …
In a research report issued today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on TG Therapeutics (NASDAQ:TGTX) and raised his price target …
In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Merrimack Pharmaceuticals (NASDAQ:MACK) with a $16 price target, …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Progenics (NASDAQ:PGNX) with a $11 price target, …
